You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
同方康泰(01312.HK)擬出售Apros Therapeutics 約79.83%股份
格隆匯 10-22 22:43

格隆匯10月22日丨同方康泰(01312.HK)公吿,於2021年10月22日,賣方同方康泰資本(公司全資附屬公司)、買方瑞傑集團有限公司及公司(作為賣方擔保人)訂立買賣協議,據此(i)賣方有條件同意出售而買方有條件同意購買銷售股份(相當於目標公司Apros Therapeutics, Inc已發行股本約79.83%,按經轉換及悉數攤薄基準及假設根據目標公司股權計劃撥備所有股份已獲發行);及(ii)賣方有條件同意促使更替而買方有條件同意購買更替貸款,總代價為1600萬美元!

於完成後,集團將不再擁有目標公司任何權益,而目標公司將不再為公司附屬公司。

目標公司為一間於美國註冊成立公司,於公吿日期為公司間接非全資附屬公司。目標公司主要從事腫瘤治療及腫瘤免疫治療研發。

目標公司主要在位於美國臨牀實驗室從事腫瘤治療及腫瘤免疫治療研發。目標公司開發技術及產品尚處於臨牀試驗階段,尚未實現商業化。公司預期在技術及產品商業化前,將進一步需要向目標公司注入大量資金進行試驗。

公司認為,交易事項乃變現其於目標公司(一直虧損且不可避免地需要大額資支出)投資的良機。集團目前亦計劃以更優化方式配置資源,集中資源推動集團在中國醫藥業務發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account